Efficacy - primary CNS
The pooled efficacy analysis of the LOXO-TRK-14001, SCOUT and NAVIGATE clinical trials included 33 patients with primary CNS tumour, 8 (24%) of which has a confirmed response [1]. Completed response was seen in 3 of the 33 patients (9%) and partial responses in 5 patients (15%). Two additional patients (6%) showed a not yet confirmed partial response and 20 patients (61%) had stable disease. Three patients (9%) had progressive disease. At the time of data cut-off, time on treatment ranged from 1.2 to 31.3 months and was ongoing in 18 out of 33 patients, with one of these patients receiving post-progression treatment.
References
- VITRAKVI® (larotrectinib), EMA Summary of medicinal Product Characteristics. 2022.